U.S. Computed Tomography Market Research Report Information by Type, by Application, by End User, by Distribution Channel, and by Region Forecast till 2032

Description

List of Tables

The U.S. Computed Tomography (CT) Market is expected to attain a value of USD 2,521.75 million, expanding at a CAGR of 7.07% during the forecast period. CT, or Computed Tomography, combines X-ray measurements taken from multiple angles with computer algorithms to produce detailed internal images of the body. It is widely used to detect diseases, monitor conditions, and guide surgical or therapeutic procedures.

The aging population with a rising number of chronic diseases is one of the crucial factors that has led the U.S. Computed Tomography (CT) market to grow. Challenges such as heart diseases, diabetes, and cancer are pushing the market in the direction of rapid and accurate diagnostic imaging. Meanwhile, innovations like low-dose CT (LDCT) and AI-powered interpretation are making preventive care programs and hospital diagnostics across the nation more reliant on CT technology.

Major Company Development

In 2024, Siemens Healthineers introduced the new generation Naeotom Alpha class with photon-counting CT technology, besides the expansion of the installations of its budget-friendly Somatom Pro.Pulse scanner. These enhancements, aimed at both higher diagnostic precision and greater accessibility, highlight the company's commitment to bringing state-of-the-art imaging to various healthcare sectors.

Key Players

Key competitors in the U.S. computed tomography (CT) market include GE Healthcare, Koninklijke Philips N.V., Stryker, Siemens Healthineers AG, Shimadzu Corporation, Mindray, FUJIFILM Holdings Corporation, NeuroLogica Corp., Carestream Dental LLC, and Canon Medical Systems Corporation.

Report Attribute Details

Market Size 2023: USD 1,353.87 Million
Market Size 2032: USD 2,521.75 Million
CAGR (2024-2032): 7.07%
Base Year: 2023
Market Forecast Period: 2024-2032

Industry Segmentations Growth

By Type: Conventional Scanners - 6.99%, Cone Beam Scanners - 8.54%.
By Application: Oncology - 7.39%, Neurology - 8.79%.
By End User: Hospitals - 6.90%, Specialty Centers - 5.66%.
By Distribution Channel: Online Channels - 8.07%, Offline Channels - 6.30%.

Product Code: MRFR/HC/62413-CR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES
- 4.2.2 EXPANSION OF CT IN TRAUMA & EMERGENCY CARE
4.3 RESTRAINTS
- 4.3.1 SHORTAGE OF SKILLED RADIOLOGISTS AND TECHNICIANS
- 4.3.2 COMPETITION FROM ALTERNATIVE IMAGING MODALITIES
4.4 OPPORTUNITY
- 4.4.1 AI INTEGRATION IN CT IMAGING
- 4.4.2 GROWING DEMAND FOR PORTABLE & POINT-OF-CARE CT SCANNERS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON US COMPUTED TOMOGRAPHY (CT) MARKET
5.3 MARKET TRENDS ON US COMPUTED TOMOGRAPHY (CT) MARKET
5.4 REGULATORY FRAMEWORK
5.5 TECHNOLOGICAL ADVANCEMENTS
5.6 PRICING ANALYSIS, 2023 (USD)
5.7 LIST OF DISTRIBUTORS OF COMPUTED TOMOGRAPHY (CT) SCANNERS IN THE US
5.8 LIST OF POTENTIAL CUSTOMERS IN THE US
5.9 TOTAL NUMBER OF COMPUTED TOMOGRAPHY (CT) INSTALLATION IN US (2019-2032)

6 US COMPUTED TOMOGRAPHY (CT) MARKET, BY TYPE

6.1 OVERVIEW
6.2 CONVENTIONAL SCANNERS
6.3 CONE BEAM SCANNERS

7 US COMPUTED TOMOGRAPHY (CT) MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 ONCOLOGY
7.3 NEUROLOGY
7.4 CARDIOVASCULAR
7.5 MUSCULOSKELETAL
7.6 ABDOMINAL & PELVIC
7.7 OTHERS

8 US COMPUTED TOMOGRAPHY (CT) MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CENTERS
8.4 DIAGNOSTIC AND IMAGING CENTER

9 US COMPUTED TOMOGRAPHY (CT) MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW
9.2 ONLINE
9.3 OFFLINE

10 US COMPUTED TOMOGRAPHY (CT) MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTHEAST
- 10.2.1 NEW YORK
- 10.2.2 PENNSYLVANIA
- 10.2.3 MASSACHUSETTS
- 10.2.4 REST OF NORTHEAST
10.3 MIDWEST
- 10.3.1 ILLINOIS
- 10.3.2 OHIO
- 10.3.3 MICHIGAN
- 10.3.4 REST OF MIDWEST
10.4 SOUTH
- 10.4.1 TEXAS
- 10.4.2 FLORIDA
- 10.4.3 GEORGIA
- 10.4.4 REST PF SOUTH
10.5 WEST
- 10.5.1 CALIFORNIA
- 10.5.2 WASHINGTON
- 10.5.3 ARIZONA
- 10.5.4 REST OF WEST

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2023
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.1.1 PRODUCT LAUNCH
- 11.1.2 PRODUCT APPROVAL
- 11.1.3 EXPANSION
- 11.1.4 PARTNERSHIP
- 11.1.5 ACQUISITION

12 COMPANY PROFILE

12.1 SIEMENS HEALTHINEERS AG
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 SHIMADZU CORPORATION
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGY
12.3 FUJIFILM HOLDINGS CORPORATION
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 MINDRAY
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
12.5 CANON MEDICAL SYSTEMS CORPORATION
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 GE HEALTHCARE
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 KONINKLIJKE PHILIPS N.V.
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 STRYKER
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 NEUROLOGICA CORP.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 CARESTREAM DENTAL LLC
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 DATA CITATIONS